[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 239
Citations 0
Invited Commentary
December 2013

The VA Advantage for Appropriate TAVR Use

Author Affiliations
  • 1Department of Surgery, University of Minnesota, Minneapolis
JAMA Surg. 2013;148(12):1093-1094. doi:10.1001/jamasurg.2013.3719

Omer et al1 in this issue of JAMA Surgery provide insight into the introduction of the SAPIEN transcutaneous aortic valve (Edwards Life Sciences) into a national health care system capable of tracking both procedural outcomes and long-term costs. The Veterans Affairs (VA) health care system is a new frontier for the use of transcatheter aortic valve replacement (TAVR) therapy. The VA patient population is diverse and complex, and the introduction of new technologies is strictly managed. As an alternative to surgical or medical therapy, TAVR provides a treatment option for patients determined to have unacceptably high, or prohibitive, operative mortality risk. There is a cohort of poor surgical candidates in this VA population for whom TAVR will be the only option for aortic valve disease treatment, and they deserve state-of-the-art technology. This study illustrates optimal implementation of an expensive new technique in a system with limited health care dollars.

First Page Preview View Large
First page PDF preview
First page PDF preview
×